C4 TherapeuticsCCCC
Market Cap: $416M
About: C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Employees: 145
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
198% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $1.18M
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
9% more funds holding
Funds holding: 104 [Q1] → 113 (+9) [Q2]
3.08% more ownership
Funds ownership: 85.25% [Q1] → 88.33% (+3.08%) [Q2]
6% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 34
41% less capital invested
Capital invested by funds: $478M [Q1] → $281M (-$197M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
BMO Capital Etzer Darout 54% 1-year accuracy 13 / 24 met price target | 233%upside $20 | Outperform Reiterated | 6 Aug 2024 |
Financial journalist opinion
Based on 3 articles about CCCC published over the past 30 days